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We report a case of a perinatally HIV-infected patient aged 9 years, who presented with right-sided hemiplegia. His initial CD4
T-cell was of 0.21% (4 cells/μL) and plasma HIV RNA virus of 185976 copies/mL (log 5.27). Plasma and CSF samples were
subsequently positive for JCV. Twelve days after the initiation of highly active antiretroviral therapy (HAART), the MRI showed
progressive white matter lesions with asymmetrical deep and subcortical white matter lesions over the left frontotemporoparietal
region and the right frontal lobe. Immune Reconstitution Inﬂammatory Syndrome (IRIS) was suspected, and the patient was
treated with methylprednisolone. His clinical symptoms worsened and despite therapy the patient deteriorated.
Copyright © 2009 Peninnah Oberdorfer et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Background
Progressive multifocal leukoencephalopathy (PML)is caused
by the JC virus (JCV). As a demyelinating disease, PML typ-
ically presents with altered mental status, motor deﬁcits, and
ataxia, and is associated with immunosuppression, especially
human immunodeﬁciency virus (HIV) [1]. Prevalence of
JCV speciﬁc antibodies increases rapidly during childhood,
but the mode of transmission is unknown [2]. PML is rare
in HIV-infected children and even more uncommonly asso-
ciated to immune reconstitution inﬂammatory syndrome
(IRIS) in children.
2.CaseReport
2.1. First Admission. A previously healthy 9-year-old boy
(whose mother was recently found to be HIV-positive)
presented to the hospital with 1 week of right-sided hemi-
plegia and right-sided facial palsy. Past medical history
included psoriasis, diagnosed 4 years prior. His only HIV
exposure was perinatal. On exam the patient weighed 22
kilograms, and vitals signs were within normal limits. He
was alert and oriented with a normal level of consciousness
and responded appropriately to questions. His speech was
slowed and slurred, but this was his baseline according to
his mother. He had right-sided facial palsy and right-sided
tongue deviation; otherwise cranial nerves were intact. The
boy had 3/5 strength in the right upper extremity and 4/5
strength in the right lower extremity. Left-sided strength was
5/5.Thepatientwasabletowalkwithlimiteddiﬃculty.Deep
tendon reﬂexes were 2+ and 3+ throughout. Babinski’s sign
showed dorsiﬂexion of the right 1st toe. Sensation was intact
throughout. The patient also had clusters of 1-2mm skin
colored papules on his forehead and left cheek in addition
to diﬀuse mild psoriatic scaling. Immunizations were up
to date. The patient was admitted for a workup of these
symptoms.
Laboratory studies showed complete blood count: hema-
tocrit 31.6%, hemoglobin 10.5g/dL, white blood cell count
5000cells/μL (N 41%, L 35%, E 12%, M 6%, B 1%, atypical
L 1%), and 157000platelets/μL. HIV-antibody test was
positive with a CD4 T-cell 0.21% (4cells/μL) and plasma2 International Journal of Pediatrics
Figure 1: CT on day 30 of onset of symptoms and 1week post-
HAART initiation.
HIV RNA virus of 185976copies/mL (log 5.27). Tests for
Cryptococcus antigen, Toxoplasmosis antigen, Ebstein Barr
virus IgG and IgM, Cytomegalovirus IgG and IgM, Hepes
Simplex virus polymerase chain reaction (PCR), Japanese
encephalitis as well as cultures for tuberculosis and fungi
(plasma and cerebrospinal ﬂuid, CSF) were all negative.
Plasma and CSF samples were positive for JCV by real time
PCR with a plasma RNA level of 226copies/mL.
Three days after admission a brain computerized tomog-
raphy (CT) scan was performed and showed frond-like
hypodense lesion at the left frontal lobe with mild eﬀace-
ment of the left frontal horn of the lateral ventricle.
Highly active antiretroviral therapy (HAART) regimen was
subsequently started 10days after admission, consisting of
GPOvir-Z (coformulated zidovudine 250mg, lamivudine
150mg, and nevirapine 200mg) [3]. Clinically, the patient
deteriorated during the 1st and 2nd weeks of HAART with
fever and increased right leg weakness, but immunologic
and virologic improvement was seen (CD4 T-cell count
0.8%, 10cells/μL, and a plasma HIV RNA viral level
of 26532copies/mL, log 4.42). CT (Figure 1)a n db r a i n
magnetic resonance imaging (MRI; Figure 2)s c a n sw e r e
subsequently performed. The scans showed progressive of
white matter lesions with asymmetrical deep and subcortical
white matter lesions over the left frontotemporoparietal
region and the right frontal lobe. The lesion on the left
hemisphere involved internal capsule, lentiform nucleus,
thalamus, and genu of corpus callosum and anterior cere-
bellar hemisphere. There were no enhanced areas after the
contrast study.
The patient was discharged 7 weeks after the ﬁrst admis-
sion. Upon discharge he was able to walk with assistance, but
was unable to speak.
2.2. Second Admission. The patient was readmitted one day
after discharge due to autonomic nervous system dysfunc-
tion (nausea, vomiting, and loss of bowel and bladder tone).
Figure 2: MRI on day 38 of onset of symptoms and 2weeks post-
HAART initiation.
Deep tendon reﬂexes were 4+ throughout, and Babinski was
positivebilaterally.Continuedimprovementofimmunologic
(CD4 T-cell count 2.0%, 30cells/μL) and virologic (HIV
RNA level 3220copies/mL, log 3.51) measures were seen.
Due to progressive neurologic symptoms HAART was
ceased. The second MRI (Figure 3)s c a nw a sp e r f o r m e d
and showed a progressive lesion in the same regions as
described in the previous MRI, but also found new lesions
over the midbrain, pons, and medulla predominantly on the
left. The patient was discharged approximately 3weeks after
admission.
2.3. Third Admission. The patient was readmitted 1month
later (100days after onset of symptoms). Immune Recon-
stitution Inﬂammatory Syndrome (IRIS) was suspected, and
the boy was treated with methylprednisolone (2mg/kg/day)
for 5days. Despite HAART suspension and administration
of steroids, his clinical symptoms worsened. The third MRI
(Figure 4)scanshowednewlesionsintheregionsoftheright
brainstem and right hemisphere with gyral enhancement.
The patient’s mother refused further treatment, he was
discharged home, and he subsequently died 1year later.
3. Summary
We report the 2nd case of IRIS associated PML in a
perinatally HIV-infected child. Since 1992 there have been
reports of 14 HIV-infected children having PML (Table 1)
[4–14]. Overall, PML in HIV-infected children has occurred
mostly in boys (9/14, 75%), with a median age of 10years
(range: 7–17). Reports have come from Brazil, Hungary,
India, Japan, South Africa, Thailand, and USA. Presenting
symptoms included: altered speech, hemiplegia, facial palsy,
and cerebellar dysfunction. All had signiﬁcant changes on
MRI or CT. Presenting CD4 T-cell counts were low, while
viral loads were high. The most common outcome was
death.International Journal of Pediatrics 3
Figure 3: 2nd MRI, 3 1/2 months after onset of symptoms, 3days
post-HAART cessation.
Neuroimaging is an important part of the diagnosis.
Multiple bilateral areas of white matter demyelination
without contrast enhancement or mass eﬀect are typical
ﬁndings. For CT imaging these appear hypodense, while
on MRI they have either decreased or increased signals
depending on the imaging parameters [14–16]. Treatment
for PML is based on HAART initiation or optimization,
which has shown improved mortality associated with lower
HIV RNA plasma viral levels and higher CD4 T-cell count
[17–20].
Although rare, cases of PML associated with IRIS occur
where there is clinical deterioration despite improvement of
immunological and virological measures after the initiation
of HAART [21, 22]. This was seen in the case reported here
and the other reported case of PML in an HIV-infected
child associated with IRIS [10]. Reported in 2004, a 12-
year-old African boy developed cerebellar dysfunction and
hemiparesis 5weeks after starting HAART. He was started
on prednisone and continued on HAART. He subsequently
had immunologic and virologic improvement with full
clinical recovery. Estimates from HIV-infected adults with
PML associated IRIS range from 9–19%, typically occurring
3–5 weeks after initiation; this is purportedly much less
common in children, as it is only sporadically mentioned
in the literature [18, 23]. Therapy for PML associated
IRIS has included glucocorticoids in addition to HAART
interruption, which have been shown to be both beneﬁcial
a n dt ob eo fn ob e n e ﬁ ti nH I V - i n f e c t e da d u l t swi t hP M L[ 10,
22, 24–26]. Our patient saw further clinical deterioration,
despite a trial of these measures unlike the boy in Africa
[10].
PML in HIV-infected adolescents has a wide distribution
ofagesandgeography.Despitethecasespresentedhere,there
is limited information about this disease in children. Under-
diagnosis is likely to both perpetuate this knowledge gap
and discourage physicians from identifying this condition.
Additionally, in developing countries, such as Thailand, lack
ofimagingandlaboratorydatamayfurtherhinderdiagnosis.
Figure 4:3rdMRI,4monthsafteronsetofsymptoms,19dayspost-
HAART cessation.
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Clinicians should then be cognizant of both of this condition
and sequelae after HAART, so that prompt diagnosis and
treatment can be made. Clear guidelines would be beneﬁcial
to clinicians who face these complex patients.
Abbreviations
3TC: Lamivudine;
AZT: Ziduvodine;
d4T: Stavudine;
ddC: Zalcitabine;
ddI: Didanosine;
EFV: Efavirenz;
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NLF: Nelﬁnavir;
NVP: Nevirapine.4 International Journal of Pediatrics
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